The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 54 , ISSUE 1 ( January-March, 2012 ) > List of Articles

Original Article

Pattern of Drug-resistance and Treatment Outcome in Multidrug-resistant Pulmonary Tuberculosis

C. Nagaraja, B.L. Shashibhushan, Mohamed Asif, PH Manjunath, C Sagar

Keywords : MDR-TB, Drug resistance, Treatment outcome

Citation Information : Nagaraja C, Shashibhushan B, Asif M, Manjunath P, Sagar C. Pattern of Drug-resistance and Treatment Outcome in Multidrug-resistant Pulmonary Tuberculosis. Indian J Chest Dis Allied Sci 2012; 54 (1):23-26.

DOI: 10.5005/ijcdas-54-1-23

License: CC BY-NC 4.0

Published Online: 16-06-2022

Copyright Statement:  Copyright © 2012; The Author(s).


Aims and Objectives. To study the pattern of drug-resistance and treatment outcomes among patients with confirmed multidrug-resistant pulmonary tuberculosis (MDR-PTB). Methods. A prospective study was conducted at Rajiv Gandhi Institute of Chest Diseases, Bengaluru, Karnataka, India. Between January 2005 and December 2008, 224 confirmed MDR-PTB cases were studied for various drug-resistance patterns, and their treatment outcomes were analysed until November 2010. Sputum culture and drug sensitivity tests (DST) were carried out at National Tuberculosis Institute, Bengaluru; DST was done for all first-line drugs except pyrazinamide. Results. Of the 224 MDR-PTB patients, 146 (65.2%) were resistant to all first-line drugs, 39 (17.4%) to isoniazid, rifampicin and streptomycin; 19 (8.5%) to isoniazid, rifampicin and ethambutol; and 20 (8.9%) to isoniazid and rifampicin. Among them, 145 (64.7%) patients were cured, 5 (2.2%) had treatment-failure, 10 (4.4%) died, and 64 (28.5%) defaulted. Among 145 cured cases, 100 (69%) were resistant to all first-line drugs, 23 (16%) to isoniazid, rifampicin and streptomycin, 11(8%) to isoniazid, rifampicin and ethambutol, and 11(8%) to isoniazid and rifampicin. Conclusions. The most common pattern observed in this study was resistance to all four first-line drugs followed by resistance to isoniazid, rifampicin and streptomycin. Patients resistant to all first-line drugs had early sputum culture conversion and better cure rate as compared to other resistance patterns. [Indian J Chest Dis Allied Sci 2012;54:23-26]

PDF Share
  1. Ramachandran R. Nalini S, Chandrashekar V, Duve PV, Sangghvi, Wares F, et al. Surviellance of drug resistance tuberculosis in the state of Gujarat, India. Int Tuberc Lung Dis 2009;13:1154-60.
  2. Mahadev B, Kumar P, Agarwal SP, Chaughan LS, Srikantaramu N. Surveillance of drug resistance to antituberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa. Indian J Tuber 2005;52:5-10.
  3. DOTS Plus guidelines. Available from: [Last accessed on 2011 Jan 15].
  4. Rao NA, Irfan M, Soomro MM, Mehfooz Z. Drug resistant pattern in multi drug resistant pulmonary tuberculosis patients. J Coll Physicians Surg Pak 2010;20:262-5.
  5. Chowgule RV, Dheodhar L. Pattern of secondary acquired drug resistant to anti tuberculosis drugs in Mumbai, India 1991-95. Indian J Chest Dis Allied Sci 1998;40:23-31.
  6. Deodhar L, Miskeen P, Chomal S. Drug resistance in tuberculosis. BHJ 1999;41:253.
  7. Janmeja AK, Raj B. Acquired drug resistance in tuberculosis in Haryana, India. J Assoc Physicians India 1998;46:194-8.
  8. Kudzawu FS, Kwara A, Flanigan T. High frequency of first line anti tuberculosis drug resistance among persons with chronic pulmonary tuberculosis at a teaching hospital chest clinic. Ghana Med J 2010;44:42-6.
  9. Joseph P, Desai VBR, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011;133:529-34.
  10. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006;10:402-8.
  11. Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri MV, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008;12:750-5.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.